For over 30 years, PharmaVentures has acted as advisor on over 1,000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide

We have unrivalled strategic insight in the commercialisation and transaction of assets and companies in the pharmaceutical, biotech, medtech and diagnostics sectors. We have been trusted by major corporations, high growth biotechs and emerging companies to provide insight and advice to help these businesses achieve their strategic goals. Operating globally in M&A, licensing, divestments and fundraising, we have the skills and experience to help you drive your business forward.

PharmaVentures attends key conferences and meetings to discuss our services and we also attend events on behalf of our clients, promoting advisory mandates in M&A and licensing across the life science sector. 

How To Meet Us

We often have opportunities that could be transformative to your business, especially with the optimal strategy and best execution.

Our team attending these events are available to speak with you about your own requirements. To book a meeting, email us at:

Upcoming events

28 February 2023

4th Annual European HealthTech CEO Forum

Asif Shahinsha will be taking part in panel discussions.


1-2 March 2023

16th Annual European Life Sciences CEO Forum

PharmaVentures will chair the Pharma Dealmakers Roundtable.


20-22 March and 28-30 March 2023

BIO-Europe Spring®

PharmaVentures’ team are taking part in 1-1 meetings online and in-person.


20-23 March 2023


Dr Jansen Jacob, Vice President, will be in New York for 1-1 meetings.


Recent events

9-12 January 2023

BIO One-on-One Partnering™ During JPM Week

PharmaVentures’ team took part in 1-1 meetings.

9-11 January 2023

Biotech Showcase™

PharmaVentures’ team attended 1-1 meetings.

5-8 December 2022

Genesis 2022

Ralph Huges presented Trends in Early Stage Deals: Pricing and Market Access and the team took part in 1-1 meetings.

14-17 November 2022


Asif Shahinsha and Andreas ​Katsiamides took part in 1-1 meetings.

1-3 November 2022

CPhI Worldwide

Dr Fintan Walton, CEO, chaired the panel discussion: Transactional Strategies to Access Future Therapeutics and Technologies which included Abbvie, Medicxi, Thermo Fisher and PharmaVentures VP, Jansen Jacob.

24-26 October 2022 


PharmaVentures’ team took part in 1-1 meetings.

4-5 October 2022 

Biopharm America

Jessie You took part in 1-1 meetings.

27 September 2022 


Enrique Bendito Moll took part in 1-1 meetings.

21-22 September 2022 

22nd Annual Biotech in Europe Forum

Dr Fintan Walton, CEO, chaired the Global Pharma-Biotech Partnering and M&A Roundtable.

20 September 2022 

9th Annual HealthTech Investment Forum

Asif Shahinsha took part in the Early Stage Investment panel discussion.

13-16 June 2022 

BIO 2022

PharmaVentures took part in 1-1 meetings.

26-27 April 2022 

BioTrinity 2022

Fotis Galiotis, Business Analyst, took part in 1-1 meetings.

28-31 March 2022 

BIO-Europe Spring

Jessie You, Associate, took part in 1-1 meetings.

22-23 March 2022 

5th Annual Neuroscience Innovation Forum

Jessie You took part in 1-1 meetings.

21-24 March 2022 


Jansen Jacob, Vice President, took part in 1-1 meetings.

9 March 2022 

N-Site Expert Advice Clinic

Adrian Dawkes, Managing Director, took part in 1-1 meetings.

1-2 March 2022 

15th Annual European Life Science CEO Forum

Dr Fintan Walton, CEO, chaired the Pharma M&A and Partnering Panel and Jessie You took part in 1-1 meetings.

28 February 2022 

3rd Annual European HealthTech CEO Forum

Jessie You took part in 1-1 meetings and Mark Andrews took part in the Innovation and Early Stage Investment panel.

PharmaVentures InSights:
The impact of conference cancellations on dealmaking
during the Covid-19 pandemic

Can Partnering Conference Cancellations Affect Dealmaking in 2020?

We all got used to the partnering conference circuit as a means to introduce the latest developments to potential partners. So now they are all temporarily suspended whilst we overcome the current global health challenge, how do you make sure your opportunities are still getting in front of your potential partners.

PharmaVentures has been successfully connecting buyers and sellers for over 29 years with and without partnering conferences.

PharmaVentures’ CEO, Dr. Fintan Walton talks about how PharmaVentures is continuing a business as usual approach for all of our clients.

Don’t hesitate to contact us to help you carry on dealmaking.